Turn Therapeutics expands GX-03 Phase 2 atopic dermatitis study after interim analysis shows broader efficacy
PUBT · 07/07 12:07
Share
Listen to the news
- Turn Therapeutics set the final Stage 2 design for its adaptive Phase 2 trial of topical GX-03 in atopic dermatitis.
- Interim analysis supported expanding enrollment to cover the full baseline EASI severity spectrum, starting at EASI ≥1.1.
- Stage 2 targets 120-135 patients, stratified by baseline EASI, with 1:1 randomization within each stratum.
- Week 4 showed the clearest treatment separation; Stage 2 adds Week 4 endpoints alongside Week 8 measures.
- Enrollment expected to finish in the fourth quarter of 2026; runway projected through the third quarter of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707654155) on July 07, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved